ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 97 filers reported holding ONCOCYTE CORP in Q3 2021. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,398 | -35.1% | 14,776 | 0.0% | 0.00% | – |
Q1 2023 | $5,237 | -2.7% | 14,776 | -11.9% | 0.00% | – |
Q4 2022 | $5,383 | -55.1% | 16,776 | 0.0% | 0.00% | – |
Q3 2022 | $12,000 | -20.0% | 16,776 | 0.0% | 0.00% | – |
Q2 2022 | $15,000 | -40.0% | 16,776 | 0.0% | 0.00% | – |
Q1 2022 | $25,000 | -55.4% | 16,776 | +6.5% | 0.00% | – |
Q3 2021 | $56,000 | – | 15,749 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 23,353,697 | $17,048,000 | 1.30% |
AWM Investment Company, Inc. | 7,746,557 | $5,655,000 | 0.86% |
PURA VIDA INVESTMENTS, LLC | 18,056,274 | $13,181,000 | 0.76% |
Defender Capital, LLC. | 2,551,980 | $1,883,000 | 0.74% |
Penbrook Management LLC | 563,350 | $411,000 | 0.35% |
ACT CAPITAL MANAGEMENT, LLC | 330,000 | $241,000 | 0.33% |
CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $55,000 | 0.04% |
Fort Sheridan Advisors LLC | 135,000 | $99,000 | 0.03% |
Orbimed Advisors | 1,882,768 | $1,374,000 | 0.03% |
WEALTH EFFECTS LLC | 51,000 | $37,000 | 0.02% |